Summary of Significant Accounting Policies (Tables)
|
3 Months Ended |
Mar. 31, 2026 |
|---|
| Accounting Policies [Abstract] |
|
| Schedule of Unrealized Gain (Loss) on Investments |
The following tables present the Company’s restricted cash equivalents and restricted investments as of March 31, 2026 and December 31, 2025, respectively. | | | | | | | | | | | | | | | | | | | | | | | | | March 31, 2026 | | Amortized Cost Basis | | Gross Unrealized Gains | | Gross Unrealized Losses | | Fair Value | | Money market funds | $ | 163,883 | | | $ | — | | | $ | — | | | $ | 163,883 | | | Corporate bonds | 897,576 | | | 2,201 | | | (631) | | | 899,146 | | | U.S. government obligations | 23,180,691 | | | 25,972 | | | (10,161) | | | 23,196,502 | | | Total | $ | 24,242,150 | | | $ | 28,173 | | | $ | (10,792) | | | $ | 24,259,531 | | | | | | | | | | | Included in restricted cash and cash equivalents | $ | 11,140,266 | | | $ | 18 | | | $ | (29) | | | $ | 11,140,255 | | | Included in restricted investments | $ | 13,101,884 | | | $ | 28,155 | | | $ | (10,764) | | | $ | 13,119,276 | |
| | | | | | | | | | | | | | | | | | | | | | | | | December 31, 2025 | | Amortized Cost Basis | | Gross Unrealized Gains | | Gross Unrealized Losses | | Fair Value | | Money market funds | $ | 161,983 | | | $ | — | | | $ | — | | | $ | 161,983 | | | Corporate bonds | 939,157 | | | 6,832 | | | — | | | 945,989 | | | U.S. government obligations | 16,102,457 | | | 102,064 | | | (497) | | | 16,204,024 | | | Total | $ | 17,203,597 | | | $ | 108,896 | | | $ | (497) | | | $ | 17,311,996 | | | | | | | | | | | Included in restricted cash and cash equivalents | $ | 1,465,903 | | | $ | 218 | | | $ | — | | | $ | 1,466,121 | | | Included in restricted investments | $ | 15,737,694 | | | $ | 108,678 | | | $ | (497) | | | $ | 15,845,875 | |
|
| Schedule of Investments Classified by Contractual Maturity Date |
The following table summarizes the contractual maturities of the Company’s restricted cash equivalents and restricted investments as of March 31, 2026 and December 31, 2025, respectively: | | | | | | | | | | | | | | | | | | | | | | | | | March 31, 2026 | | December 31, 2025 | | Amortized Cost | | Fair Value | | Amortized Cost | | Fair Value | | Within 1 year | $ | 16,159,291 | | | $ | 16,161,428 | | | $ | 6,760,198 | | | $ | 6,762,886 | | | After 1 year through 5 years | 3,436,826 | | | 3,438,697 | | | 6,118,800 | | | 6,159,400 | | | After 5 years through 10 years | 4,646,033 | | | 4,659,406 | | | 4,324,599 | | | 4,389,710 | | | Total | $ | 24,242,150 | | | $ | 24,259,531 | | | $ | 17,203,597 | | | $ | 17,311,996 | |
|
| Schedule of Estimated Useful Lives |
A summary of estimated useful lives is as follows: | | | | | | | | | | | Estimated Useful Life | | Buildings | | 39 years | | Office equipment and furniture | | 3-7 years | | Vehicles | | 5-8 years | | Medical and other plant equipment | | 5 years | | Leasehold improvements | | Shorter of useful life of asset or lease term |
|
| Schedule of Disaggregation of Revenue |
In the following table, revenues are disaggregated as follows: | | | | | | | | | | | | | | | | Revenue Breakdown | | Three Months Ended
March 31, | | | 2026 | | 2025 | | Primary Geographical Markets | | | | | | U.S. | | $ | 62,739,240 | | | $ | 81,974,416 | | | U.K. | | 12,811,244 | | | 14,058,639 | | | Total revenues | | $ | 75,550,484 | | | $ | 96,033,055 | | | | | | | | Major Segments | | | | | | Mobile Health Services | | $ | 23,625,247 | | | $ | 45,209,544 | | | Transportation Services | | 51,925,237 | | | 50,823,511 | | | Total revenues | | $ | 75,550,484 | | | $ | 96,033,055 | |
|
| Schedule of Earnings Per Share, Basic and Diluted |
The following table presents the calculation of basic and diluted net loss per share to stockholders of DocGo Inc. and Subsidiaries: | | | | | | | | | | | | | Three Months Ended
March 31, | | 2026 | | 2025 | | Net loss attributable to stockholders of DocGo Inc. and Subsidiaries | $ | (14,763,131) | | | $ | (9,405,315) | | | Weighted-average shares outstanding - Basic | 98,746,095 | | | 101,594,579 | | | Effect of dilutive options | — | | | — | | | Weighted-average shares outstanding - Diluted | 98,746,095 | | | 101,594,579 | | | Net loss per share attributable to DocGo Inc. and Subsidiaries - Basic | $ | (0.15) | | | $ | (0.09) | | | Net loss per share attributable to DocGo Inc. and Subsidiaries - Diluted | $ | (0.15) | | | $ | (0.09) | | | Anti-dilutive employee share-based awards excluded | 16,890,381 | | | 7,131,017 | |
|